134 related articles for article (PubMed ID: 32144722)
1. Development of a Neuroprotective Erythropoietin Modified with a Novel Carrier for the Blood-Brain Barrier.
Chiu PC; Liou HC; Ling TY; Shen LJ
Neurotherapeutics; 2020 Jul; 17(3):1184-1196. PubMed ID: 32144722
[TBL] [Abstract][Full Text] [Related]
2. The relationship between erythropoietin pretreatment with blood-brain barrier and lipid peroxidation after ischemia/reperfusion in rats.
Bahcekapili N; Uzüm G; Gökkusu C; Kuru A; Ziylan YZ
Life Sci; 2007 Mar; 80(14):1245-51. PubMed ID: 17300815
[TBL] [Abstract][Full Text] [Related]
3. Targeted delivery of erythropoietin by transcranial focused ultrasound for neuroprotection against ischemia/reperfusion-induced neuronal injury: a long-term and short-term study.
Wu SK; Yang MT; Kang KH; Liou HC; Lu DH; Fu WM; Lin WL
PLoS One; 2014; 9(2):e90107. PubMed ID: 24587228
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of erythropoietin pretreatment in a rodent model of transient middle cerebral artery occlusion.
Ratilal BO; Arroja MM; Rocha JP; Fernandes AM; Barateiro AP; Brites DM; Pinto RM; Sepodes BM; Mota-Filipe HD
J Neurosurg; 2014 Jul; 121(1):55-62. PubMed ID: 24702327
[TBL] [Abstract][Full Text] [Related]
5. The erythropoietin-derived peptide MK-X and erythropoietin have neuroprotective effects against ischemic brain damage.
Yoo SJ; Cho B; Lee D; Son G; Lee YB; Soo Han H; Kim E; Moon C; Moon C
Cell Death Dis; 2017 Aug; 8(8):e3003. PubMed ID: 28817120
[TBL] [Abstract][Full Text] [Related]
6. Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease.
Chang R; Al Maghribi A; Vanderpoel V; Vasilevko V; Cribbs DH; Boado R; Pardridge WM; Sumbria RK
Mol Pharm; 2018 Nov; 15(11):4963-4973. PubMed ID: 30252487
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin delivered via intra-arterial infusion reduces endoplasmic reticulum stress in brain microvessels of rats following cerebral ischemia and reperfusion.
Zhao H; Wang R; Wu X; Liang J; Qi Z; Liu X; Min L; Ji X; Luo Y
J Neuroimmune Pharmacol; 2015 Mar; 10(1):153-61. PubMed ID: 25626440
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin and Nrf2: key factors in the neuroprotection provided by apo-lactoferrin.
Zakharova ET; Sokolov AV; Pavlichenko NN; Kostevich VA; Abdurasulova IN; Chechushkov AV; Voynova IV; Elizarova AY; Kolmakov NN; Bass MG; Semak IV; Budevich AI; Kozhin PM; Zenkov NK; Klimenko VM; Kirik OV; Korzhevskii DE; Menshchikova EB; Vasilyev VB
Biometals; 2018 Jun; 31(3):425-443. PubMed ID: 29748743
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin as a new therapeutic opportunity in brain inflammation and neurodegenerative diseases.
Merelli A; Czornyj L; Lazarowski A
Int J Neurosci; 2015; 125(11):793-7. PubMed ID: 25405533
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotection by erythropoietin administration after experimental traumatic brain injury.
Grasso G; Sfacteria A; Meli F; Fodale V; Buemi M; Iacopino DG
Brain Res; 2007 Nov; 1182():99-105. PubMed ID: 17935704
[TBL] [Abstract][Full Text] [Related]
11. Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse.
Zhou QH; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Brain Res; 2011 Mar; 1382():315-20. PubMed ID: 21276430
[TBL] [Abstract][Full Text] [Related]
12. Combination of tissue-plasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice.
Zechariah A; ElAli A; Hermann DM
Stroke; 2010 May; 41(5):1008-12. PubMed ID: 20360548
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotection in experimental stroke in the rat with an IgG-erythropoietin fusion protein.
Fu A; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Brain Res; 2010 Nov; 1360():193-7. PubMed ID: 20833153
[TBL] [Abstract][Full Text] [Related]
14. Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse.
Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2010 Dec; 7(6):2148-55. PubMed ID: 20860349
[TBL] [Abstract][Full Text] [Related]
15. Amelioration of cerebral ischemia-reperfusion injury based on liposomal drug delivery system with asialo-erythropoietin.
Ishii T; Asai T; Oyama D; Fukuta T; Yasuda N; Shimizu K; Minamino T; Oku N
J Control Release; 2012 May; 160(1):81-7. PubMed ID: 22342472
[TBL] [Abstract][Full Text] [Related]
16. Intrinsic and extrinsic erythropoietin enhances neuroprotection against ischemia and reperfusion injury in vitro.
Liu R; Suzuki A; Guo Z; Mizuno Y; Urabe T
J Neurochem; 2006 Feb; 96(4):1101-10. PubMed ID: 16417583
[TBL] [Abstract][Full Text] [Related]
17. Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse.
Boado RJ; Hui EK; Lu JZ; Pardridge WM
J Pharmacol Exp Ther; 2010 Jun; 333(3):961-9. PubMed ID: 20233799
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotection in stroke in the mouse with intravenous erythropoietin-Trojan horse fusion protein.
Fu A; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Brain Res; 2011 Jan; 1369():203-7. PubMed ID: 21047502
[TBL] [Abstract][Full Text] [Related]
19. Combination of deferoxamine and erythropoietin: therapy for hypoxia-ischemia-induced brain injury in the neonatal rat?
van der Kooij MA; Groenendaal F; Kavelaars A; Heijnen CJ; van Bel F
Neurosci Lett; 2009 Feb; 451(2):109-13. PubMed ID: 19103262
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system.
Zhang Y; Pardridge WM
Stroke; 2001 Jun; 32(6):1378-84. PubMed ID: 11387502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
